Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 4/20 | 0.77 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.77 |
| ▸ | MEN1 | O00255 | 8/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTR2B | P41595 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.56 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5821507 | 0.91 | CYP2C9 (0.71) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL5823065 | 0.89 | HSD11B1 (0.69) | CYP2C9CYP2C19MAPK14NPC1HTT | |
| SCHEMBL3883491 | 0.89 | MAPK14 (0.60) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL5820252 | 0.89 | CYP2C9 (0.77) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL13791955 | 0.88 | CYP2C9 (0.60) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL7234983 | 0.87 | CYP2C9 (1.00) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL159145 | 0.86 | CYP2C9 (0.72) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL3874271 | 0.85 | CYP2C9 (0.55) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL9785782 | 0.84 | LTB4R (0.64) | CYP2C9CYP2C19MAPK14MEN1KMT2A | |
| SCHEMBL13791958 | 0.82 | CYP2C9 (0.52) | CYP2C9CYP2C19MAPK14MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002523448-A | — | — | 2002-07-30 | — | — | JP | claimed |
| US-6410540-B1 | HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-06-25 | — | — | US | claimed |
| EP-1107758-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012074-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2000-03-09 | — | — | WO | claimed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20060241150-A1 | P38 kinase inhibitor compositions and methods of using the same | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2006-10-26 | — | — | US | disclosed |
| EP-1631145-A2 | P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USING THE SAME | The Trustees of The University of Pennsylvania (US) | 2006-03-08 | — | — | EP | disclosed |
| WO-2005000405-A2 | P38 KINASE INHIBITOR COMPOSITIONS AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2005-01-06 | — | — | WO | disclosed |
| US-6541477-B2 | Treating inflammation and cardiac conditions with compositions containing acylated piperazine or piperidine rings coupled to phenyl and other aryl groups, such a furan or thiophene | SCIOS, INC. | 2003-04-01 | — | — | US | disclosed |
| US-20020115671-A1 | Inhibitors of p38-a kinase | SCIOS, INC. | 2002-08-22 | — | — | US | disclosed |
| US-6410540-B1 | HEART AND KIDNEY DISEASES; ANTIINFLAMMATORY AGENTS | SCIOS, INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2001064676-A2 | INHIBITORS OF p38-α KINASE | SCIOS, INC. (US) | 2001-09-07 | — | — | WO | disclosed |
| EP-1107758-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012074-A2 | USE OF PIPERIDINES AND/OR PIPERAZINES AS INHIBITORS OF P38-ALPHA KINASE | SCIOS INC. (US) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241150-A1 | P38 kinase inhibitor compositions and methods of using the same | MAPK7, MAPK1, MAP3K7 | CYP2C9 4510/4885CYP2C19 4413/4885MAPK14 19/4885 |
| US-20020115671-A1 | Inhibitors of p38-a kinase | MAPK1, MAP3K1, MAP3K6 | CYP2C9 4360/4885CYP2C19 3780/4885MAPK14 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.